A 65-year-old client started on warfarin 5 mg orally daily a… | MyMerci
Adverse Effects/Contraindications/InteractionsPA
Question
A 65-year-old client started on warfarin 5 mg orally daily and concurrent therapeutic enoxaparin 3 days ago for a new pulmonary embolism. Today the INR is 1.2. The client has no active bleeding and is hemodynamically stable. Which interpretation by the nurse is correct?
1The warfarin dose is too low and should be doubled today.
2The warfarin is failing; switch to apixaban immediately.
3INR 1.2 means the client is anticoagulated; stop the enoxaparin today.
4INR of 1.2 on day 3 is consistent with the typical warfarin warm-up — therapeutic INR is usually reached around days 5-7; continue enoxaparin per protocol, do NOT discontinue, and recheck INR per provider schedule. Warfarin dose adjustment is by the prescriber based on INR trend and target.✓ Correct answer
Explanation
Day 3 INR 1.2 — expected warm-up Warfarin onset takes 5-7 days. INR begins to drift up after factor II (longest half-life ~60 hours) declines. Day 3 INR of 1.2 is expected and not a treatment failure. The patient is protected by the parenteral agent during this warm-up.
Key teaching/practice points: • Continue parenteral anticoagulant until both criteria are met: ≥5 days of warfarin AND INR ≥2.0 for ≥24 hours. • Do NOT double the warfarin dose based on a day-3 INR; dose adjustments use anticipated trend, dose-response algorithms, and clinical context. • Some patients reach therapeutic INR earlier or later — typical warfarin sensitivity, age, weight, drug/diet interactions, genetics (CYP2C9, VKORC1) affect kinetics. • If the patient develops new bleeding or thrombosis during warm-up, re-evaluate. • Switching to a DOAC (apixaban, rivaroxaban) can be considered as a clinical decision but is not the response to a normal warm-up INR. • Standard NCLEX testing point: INR 1.2 on day 3 = continue current plan, NOT a failure.
In-depth explanation
Clinical reasoning summary Day 3 INR 1.2 — expected warm-up Warfarin onset takes 5-7 days. INR begins to drift up after factor II (longest half-life ~60 hours) declines. Day 3 INR of 1.2 is expected and not a treatment failure. The patient is protected by the parenteral agent during this warm-up.
Key teaching/practice points: • Continue parenteral anticoagulant until both criteria are met: ≥5 days of warfarin AND INR ≥2.0 for ≥24 hours. • Do NOT double the warfarin dose based on a day-3 INR; dose adjustments use anticipated trend, dose-response algorithms, and clinical context. • Some patients reach therapeutic INR earlier or later — typical warfarin sensitivity, age, weight, drug/diet interactions, genetics (CYP2C9, VKORC1) affect kinetics. • If the patient develops new bleeding or thrombosis during warm-up, re-evaluate. • Switching to a DOAC (apixaban, rivaroxaban) can be considered as a clinical decision but is not the response to a normal warm-up INR. • Standard NCLEX testing point: INR 1.2 on day 3 = continue current plan, NOT a failure.